Pfizer announced on Thursday that it is progressing with the development of a once-daily weight loss pill, which it believes could be a strong contender in the GLP-1 market. Meanwhile, the U.S. Food and Drug Administration (FDA) did not approve Novo Nordisk’s once-weekly insulin. Additionally, a report from the U.S. Federal Trade Commission (FTC) stated that pharmacy benefit managers (PBMs) are driving up drug prices.
Explore these stories and other notable pharmaceutical news from this week.
Related Recipes
Trending Now
Fox News Dispatches Beijing Team for Exclusive First Post-Summit Interview With Trump After Trump-Xi Talks
Schroder’s Limited Minutes Hamper Cavs in Game 7 Win Over Raptors
Luna accuses CIA of seizing 40 MLK and JFK files from Tulsi Gabbard’s ODNI office
Chennedy Carter Targets 2026 Sixth Player of the Year with the Las Vegas Aces
Continue Reading
